PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics

PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics

Ambry Genetics via YouTube Direct link

Intro

1 of 37

1 of 37

Intro

Class Central Classrooms beta

YouTube videos curated by Class Central.

Classroom Contents

PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics

Automatically move to the next video in the Classroom when playback concludes

  1. 1 Intro
  2. 2 Disclosures
  3. 3 OUTLINE
  4. 4 GOALS LEARNING OBJECTIVES
  5. 5 Cancer Probability for Females at Birth - USA
  6. 6 Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
  7. 7 EPITHELIAL OVARIAN CANCER SIGNS
  8. 8 OVARIAN CANCER CLASSIFICATION
  9. 9 Epithelial Ovarian Cancer Cont... Five main histologic subtypes
  10. 10 Regulatory Pathways
  11. 11 Mucinous Carcinoma
  12. 12 Standard of Care
  13. 13 Chemotherapy Recurrent Disease Platinum Sensitive
  14. 14 Conventional Chemotherapy Side Effects
  15. 15 Cost Comparison Among Ovarian Cancer Treatments
  16. 16 Hereditary Susceptibility to
  17. 17 Clinical manifestation of hereditary ovarian cancer
  18. 18 LIFETIME RISK ESTIMATED IN BRCA1 & BRCA2 CARRIERS
  19. 19 BRCA1-RELATED OVARIAN CANCER
  20. 20 Hereditary breast and ovarian cancer syndrome (HBOC)
  21. 21 Targeted Therapies
  22. 22 Poly(ADP-Ribose) Polymerase (PARP) inhibition in ovarian cancer
  23. 23 PARP Inhibitors: Mechanism of Action
  24. 24 PARP Family
  25. 25 PARP Inhibitors Background
  26. 26 High Grade Serous Cancers (HGSC) & BRCA mutations
  27. 27 Phase I trial: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
  28. 28 Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
  29. 29 PARP Inhibitors: Properties & Side Effects
  30. 30 Olaparib Clinical Trials
  31. 31 Ovarian cancer trials PARP 1 & 2 Inhibitors
  32. 32 Targeting Angiogenesis: VEGF
  33. 33 VEGF: Tyrosine kinase Inhibitor
  34. 34 Randomized phase II trial: Olaparib with Cediranib vs Olaparib alone in recurrent platinum sensitive
  35. 35 PARP Inhibitor Side effect Profile
  36. 36 In Summary
  37. 37 Targeting Therapies: Summary

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.